Home > Resources > Whitepapers > A Dose of Shared Services: Why Big Pharma is Turning South

A Dose of Shared Services: Why Big Pharma is Turning South

With blockbuster drugs coming off patent, rising research and development costs and profit margins growing ever slimmer, biotechnology and pharmaceutical companies are feeling the pressure to find every business advantage they can. One of the symptoms of that pressure has been a kaleidoscope of innovative business decisions. While this momentum ultimately strengthens a company’s position, transformations inevitably create uncertainty and challenges as companies grapple with reinventing their operating model and business processes.

Spotlight

ProMetrics

Over two decades of dedicated service to the pharmaceutical industry has allowed us to become experts in data analytics and decision support for pharmaceutical brands. Today, we play an intricate role in helping pharmaceutical manufacturers execute their strategies.

OTHER WHITEPAPERS

Global Use of Medicines 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

The Globalization Of The Pharmaceutical Industry

whitePaper | July 7, 2023

Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

A Dose of Shared Services: Why Big Pharma is Turning South